In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate

Current Eye Research

Volumn 37, Issue 7, 2012, Pages 567-574

  Dib, Eduardo ^a   Maia, Mauricio ^a   Lima, Acácio De Souza ^b   De Paula Fiod Costa, Elaine ^a   De Moraes Filho, Milton Nunes ^a   Rodrigues, Eduardo Büchele ^a   Penha, Fernando Marcondes ^a   Coppini, Larissa Pereira ^a   De Barros, Nilana Meza Tenório ^a   Coimbra, Rita De Cassia Sinigaglia Galli ^a   Magalhães Jr , Octaviano ^a   Guerra, Tarcisio ^a   Furlani, Bruno De Albuquerque ^a   Freymuller, Edna ^a   Farah, Michel Eid ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Ocular Pharmacology Sector   (Brazil)

Author keywords

Angiogenesis; Choroidal neovascularization; Drug toxicity; Intravitreal injection; Tyrosine kinase inhibitor

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CELL CULTURE; DRUG EFFECT; DRUG TARGETING; ELECTRORETINOGRAM; ENDOTHELIUM CELL; ENUCLEATION; EYE; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROSCOPY; NONHUMAN; PHOTOGRAPHY; PHOTORECEPTOR; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RABBIT; RETINA INJURY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TOXICITY TESTING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL COUNT; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRORETINOGRAPHY; ENDOTHELIUM, VASCULAR; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOLES; INTRAVITREAL INJECTIONS; PHOTORECEPTOR CELLS, VERTEBRATE; PROTEIN-TYROSINE KINASES; PYRROLES; RABBITS; RETINAL GANGLION CELLS; RETINAL PIGMENT EPITHELIUM; UMBILICAL VEINS;

EID: 84862170803     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.635916     Document Type: Article

References (33)

1. Friedman DS, O'Colmain BJ, Muñoz B et al.; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572. (Pubitemid 38456293)
2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999;117:1329-1345.
3. Arnold J. Age related macular degeneration. Clin Evid. 2006;15:877-888.
4. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: A review of association. Eye (Lond). 2005;19:935-944. (Pubitemid 43114972)
5. Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology. 2006;113:2002.e1-2002.12.
6. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR; MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114: 246-252. (Pubitemid 46172497)
7. Arevalo JF, Fromow-Guerra J, Sanchez JG et al.; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in agerelated macular degeneration: Results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina (Philadelphia, Pa). 2008;28:1387-1394.
8. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695.e1-1695.15.
9. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65.e5.
10. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation. Health Technol Assess. 2008;12:iii-iv, ix.
11. Lalwani GA, Rosenfeld PJ, Fung AE et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58.e1.
12. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelveweek results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047. (Pubitemid 40797459)
13. Wu L, Arevalo JF, Roca JA et al.; Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina (Philadelphia, Pa). 2008;28:212-219. (Pubitemid 351643150)
14. Sutent - Labeling Text. Pfizer Labs. 2006 Jan.
15. Paschoalin T, Carmona AK, Rodrigues EG et al. Characterization of thimet oligopeptidase and neurolysin activities in B16F10-Nex2 tumor cells and their involvement in angiogenesis and tumor growth. Mol Cancer. 2007;6:44.
16. ARVO. ARVO Animals in Research Committee. In: ARVO (ed.). ARVO Animals in Research Committee. USA: ARVO; 1996: pp. 1, 20.
17. Price N, Gottfried MR, Clary E et al. Safety and efficacy of India ink and indocyanine green as colonic tattooing agents. Gastrointest Endosc. 2000;51:438-442. (Pubitemid 30204764)
18. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M; International Society for Clinical Electrophysiology of Vision. ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol. 2009;118:69-77.
19. Zemel E, Loewenstein A, Lei B, Lazar M, Perlman I. Ocular pigmentation protects the rabbit retina from gentamicin-induced toxicity. Invest Ophthalmol Vis Sci. 1995;36:1875-1884.
20. Kwok AK, Lai TY, Yeung CK, Yeung YS, Li WW, Chiang SW. The effects of indocyanine green and endoillumination on rabbit retina: An electroretinographic and histological study. Br J Ophthalmol. 2005;89:897-900. (Pubitemid 40904817)
21. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci. 2007;48:1773-1781. (Pubitemid 351261365)
22. Rodrigues EB, Penha FM, Farah ME et al. Preclinical investigation of the retinal biocompatibility of six novel vital dyes for chromovitrectomy. Retina (Philadelphia, Pa). 2009;29:497-510.
23. Penha FM, Maia M, Farah ME et al. Morphologic and clinical effects of subretinal injection of indocyanine green and infracyanine green in rabbits. J Ocul Pharmacol Ther. 2008;24:52-61. (Pubitemid 351156632)
24. Penha FM, Maia M, Eid Farah M et al. Effects of subretinal injections of indocyanine green, trypan blue, and glucose in rabbit eyes. Ophthalmology. 2007;114:899-908.
25. Maia M, Kellner L, de Juan E Jr et al. Effects of indocyanine green injection on the retinal surface and into the subretinal space in rabbits. Retina (Philadelphia, Pa). 2004;24:80-91. (Pubitemid 38240845)
26. Rodrigues EB, Penha FM, de Paula Fiod Costa E et al. Ability of new vital dyes to stain intraocular membranes and tissues in ocular surgery. Am J Ophthalmol. 2010;149:265-277.
27. Korpanty G, Sullivan LA, Smyth E, Carney DN, Brekken RA. Molecular and clinical aspects of targeting the VEGF pathway in tumors. J Oncol. 2010;2010:652320.
28. Ropert S, Vignaux O, Mir O, Goldwasser F. VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption. Invest New Drugs. 2011;29:1497-1499.
29. Sablin MP, Dreyer C, Colichi C et al. Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development. Expert Opin Drug Metab Toxicol. 2010;6:1005-1015.
30. Narayanan R, Mungcal JK, Kenney MC, Seigel GM, Kuppermann BD. Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci. 2006;47:722-728. (Pubitemid 46768403)
31. Maia M, Margalit E, Lakhanpal R et al. Effects of intravitreal indocyanine green injection in rabbits. Retina (Philadelphia, Pa). 2004;24:69-79. (Pubitemid 38240844)
32. Veckeneer M, van Overdam K, Monzer J et al. Ocular toxicity study of trypan blue injected into the vitreous cavity of rabbit eyes. Graefes Arch Clin Exp Ophthalmol. 2001;239:698-704. (Pubitemid 32927021)
33. Sugawara T, Sieving PA, Bush RA. Quantitative relationship of the scotopic and photopic ERG to photoreceptor cell loss in light damaged rats. Exp Eye Res. 2000;70:693-705.